I am an oncologist with interests in using machine learning and Omics to develop precision-based treatment paradigms and study therapuetic resistance. My laboratory efforts leverage Omics-based techniques, medical imaging (e.g., radiology, pathology), and machine learning to define and target genomic and metabolic vulnerabilities for these tumors. My hope is that these efforts will result in improved biomarkers to re-define precision-based treatments for patients.


MD, Medical College of Georgia

Select Publications

1. Brastianos PK*, Kim AE*, Wang N, Lee EQ, Ligibel J, Cohen JV, et al. Palbociclib demonstrates intracranial activity inprogressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nat Cancer 2, 498-502 (2021). (*denotes equal authorship)

2. Prakadan SM*, Alvarez-Breckenridge CA*, Markson SC*, Kim AE, Klein RH, Nayyar N, et al. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nature Comms 12,5955 (2021).

3. Brastianos PK*, Kim AE*, Giobbie-Hurder A, Lee EQ, Lin NU, Overmoyer B, et al. Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. Nature Medicine 29, 1728-1737 (2023). (*denotes equal authorship)

4. Kim AE, Nieblas-Bedolla E, de Sauvage MA, Brastianos PK. Leveraging translational insights towards precision medicine approaches for brain metastases. Nat Cancer 4, 955-967 (2023).


Damon Runyon Cancer Research Foundation Physician Scientist Award
American Association of Cancer Research Breast Cancer Research Fellowship
American Brain Tumor Association Basic Research Fellowship
American Society of Clinical Oncology Young Investigator Award
American Society of Clinical Investigation Emerging-Generation Award